“Variant‐specific discrepancy when quantitating BCR‐ABL1 e13a2 and e14a2 transcripts using the Europe Against Cancer qPCR assay.” Is dPCR the key?

Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation

(2019) Simona Bernardi et al.   Cancer Medicine

E14a2 BCR-ABL1 transcript is associated with a higher rate of treatment-free remission in individuals with chronic myeloid leukemia after stopping tyrosine kinase inhibitor therapy

(2017) Simone Claudiani et al.   HAEMATOLOGICA

No influence of BCR-ABL1 transcript types e13a2 and e14a2 on long-term survival: results in 1494 patients with chronic myeloid leukemia treated with imatinib

(2017) Markus Pfirrmann et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

E14a2 BCR-ABL1 transcript is associated with a higher rate of treatment-free remission in individuals with chronic myeloid leukemia after stopping tyrosine kinase inhibitor therapy

(2017) Simone Claudiani et al.   HAEMATOLOGICA

De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial

(2017) Richard E Clark et al.   Lancet Haematology

Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors

(2016) P. Jain et al.   BLOOD